We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 15 days, there were significant gains in mesopic low ...
FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A second phase 3 pivotal clinical trial investigating ...
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following ...
Opus Genetics, Inc. announced positive results from its Phase 3 clinical trial, LYNX-2, which evaluated Phentolamine Ophthalmic Solution 0.75% for treating chronic night driving impairment in ...
Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for treating presbyopia, achieving its primary and key ...
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating ...
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related ...
Opus Genetics (IRD) said that the FDA has granted Fast Track designation for Phentolamine Ophthalmic Solution 0.75% as a potential treatment for chronic night driving impairment and debilitating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results